Psychology Today50%
Single Dose Psilocybin Led to Robust Antidepressant Response 22%
By Lori Plutchik M.D.37%
7/12/2026, 5:12:19 PM
BS Summary: This article contains 14 faulty reasoning types, including Framing Effect, Anchoring Bias, and Hasty Generalization, with Optimism Bias as the most egregious example at 19.4% saturation with 237 hits. Analysis detected 848 faulty-reasoning hits from 1,222 analyzed words, generating a BS Score of 35.5% and a BS Rank of 22% (12,334 of 15,675 articles). This article is better (less manipulative) than 78.70% of the article peer group.
The Colors of Contemporary Psychiatry
Take our Depression Test
Find a therapist to overcome depression
Results of this study showed significant rapid response to a single dose of oral psilocybin 25 mg vs placebo.
At 6 weeks the psilocybin treatment group had remission rates of 52.9% vs 5.9% for the placebo group.
Psilocybin has been shown to have low addictive potential.
Psilocybin: from restricted to accelerated research
The excitement around psilocybin research for treatment of depressive disorders has spurred momentum worldwide.
Psilocybin, a naturally occurring hallucinogen found in over 200 species of mushrooms, has long been recognized as having profound psychoactive effects (Smausz et al, 2022).
However the Controlled Substances Act of 1970 severely restricted research on hallucinogenic and psychedelic substances.
It was not until 1992 that the National Institute on Drug Abuse and the FDA, recognizing the potential benefits of psychedelic drugs, removed restrictions and permitted psychedelic research to include human subjects (Doblin, 1992).
Since then, rstudies evaluating psilocybin as a potential option for the treatment of depressive disorders have surged (Nichols, 2000; Smausz, 2022 ).
On April 18, 2026, President Trump signed an executive order further accelerating research and expanding access to psychedelic drugs for serious mental illnesses.
Properties of psilocybin
Psilocybin itself does not exhibit much effect until it undergoes a metabolic conversion in the body to psilocin, the pharmacologically active compound.
Psilocin, a 5-HT serotonin receptor agonist, binds strongly to 5-HT2A receptors, and to a lesser extent 5-HT1A and 5-HT2C receptors (Adeyinks et al, 2025).
Psilocybin has consistently been shown to have a low potential for addiction and is considered the safest of the psychedelic drugs (Metaxa et al, 2024; Adeyinka, 2025).
New treatments urgently needed for depression
Depression affects an estimated 300 million people worldwide and is a leading cause of disability (Metaxa, 2024).
Antidepressants have transformed treatment, but they do not work for everyone.
Some patients have inadequate responses, and others cannot tolerate the side effects.
Even when the drugs do work, it can takes several weeks before a person notices any benefit, and full remission can take months (Metaxa, 2024).
Depression often behaves like a chronic illness , with a high likelihood of relapse without treatment, especially in those who have experienced multiple episodes.
New study shows benefits of single dose psilocybin for depressive disorder
A Swedish study published in May 2026 in the Journal of the American Medical Association (JAMA) found that a single dose of psilocybin improved depression quickly and benefits continued for months (Yngwe et al, 2026).
What made the study unusual was its design: a double-blind, placebo -controlled randomized clinical trial in patients with moderate to severe recurrent major depressive disorder (MDD).
According to the authors, this design has not been used before in psilocybin research for MDD.
Earlier trials focused on patients with treatment resistant depression (TRD) and on cancer related depression.
However, patients with MDD comprise a substantial cohort that can benefit immensely from the rapid mood boost (Yngwe, 2026).
The study design matters because it limits bias .
Patients are assigned by chance to receive either psilocybin or a placebo, and neither the patients nor the researchers know who is in which group.
Double-blind RCT’s typically have high internal validity for assessing treatment response.
Concerns with prior studies relate to the inclusion of past psychedelic users as well as the use of crossover designs in which both groups sequentially received the same treatments.
This study excluded participants with a history of psychedelic use.
The study methods and results
The primary objective was to assess the antidepressant effects of a single, 25 mg oral dose of psilocybin in patients with MDD by day 8.
Thirty-five participants who were diagnosed with moderate to severe MDD were included with 17 patients randomized to the psilocybin group and 18 to the placebo group (the placebo used in the study was a vitamin called niacin).
Participants received a single dose of either psilocybin 25 mg or placebo (niacin 100 mg) in identical appearing capsules.
Over the course of 17 days they also received 5 psychotherapeutic support sessions.
Response to treatment was measured by the Montgomery-Asberg Depression Rating Scale (MADRS).
This clinician administered scale measures 10 areas affected by depression, including mood, sleep, appetite , pessimism and suicidal thoughts.
Each section is scored on a scale of 0-6 with higher total scores indicating more severe depressive symptoms.
The study successfully met its endpoint showing a significant improvement in depressive symptoms, with a mean reduction of 7.27 points on the MADRS (95% CI, P=0.01) in patients who received psilocybin compared to placebo at day 8 of treatment.
In addition, significant improvement in the psilocybin group versus the placebo group was present on days 15 and 42.
At 6 weeks the psilocybin group had a remission rate of 52.9% compared to 5.9% for the placebo group.
The beneficial effects noted in the psilocybin group versus placebo were no longer noted at 12 months.
Separately, the patient self-rated version of the scale, known as MADRS-S, revealed a significant reduction in depressive symptoms in the psilocybin group over the placebo group already at day 2.
This improvement persisted for more than 3 months (through day 102) as did other secondary outcomes that were measured such as quality of life and functional disability.
Psilocybin was generally well tolerated with some reports of transient mild to moderate side effects.
Two participants in the psilocybin group reported persistent, severe anxiety and required additional medical support.
Limitations of the study include the modest sample size of 35 patients, possible expectation bias related to the self-selection of patients and the use of physicians who were involved in the study as raters which may have decreased blinding accuracy.
Depression Essential Reads
Treating Depression by Calming the Immune System
4 Things That Help Depression More Than You May Think
Given that depressive disorders affect hundreds of millions of individuals, the urgency to find new treatments that will improve clinical outcomes, shorten response times and decrease side effects is clear.
Maintenance of rigorous standards for research methodology is imperative in this process of new drug development.
Psilocybin remains a promising additional treatment for recurrent depressive disorders due to its rapid onset of action and potential benefits for relapse prevention.
Adeyinka, D., Forsyth, D., Currie, S., Faraone, N., (2025).
Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models.
Front.
Syst.
Neurosci.
Vol 19. https://doi.org/10.3389/fnsys.2025.1585367
Doblin, R.
(1992).
The historic FDA and NIDA Meetings on Hallucinogens.
Newsletter of the Multidisciplinary Association for Psychedelic Studies MAPS.
Vol 3(3). https://maps.org/news-letters/v03n3/03302fda.html
Metaxa, A., Clarke, M., (2024).
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.
BMJ.
385. https://www.bmj.com/content385/bmj-2023-078084
Nichols, D., (2000).
Psilocybin: from ancient magic to modern medicine.
The Journal of Antibiotics.
73. https://www.nature.com/articles/s41429-020-0311-8
Smausz, R., Neill, J., Gigg, J., (2022).
Neural mechanisms underlying psilocybin’s therapeutic potential-the need for preclinical in vivo electrophysiology.
J Psychopharmacol.
36(7). https://doi.org/10.1177/02698811221092508
Yngwe, H., Plaven-Sigray, P., Emmanuel, C.J., Henje, E., Berglund, A., Tiger, M., Beckman, M., Lindbergh, J., (2026).
Short-term and late-term effects of psilocybin on symptoms in major depression: a randomized clinical trial.
JAMA.
Vol 9 (5). https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2849099
Lori Plutchik, M.D., is a board-certified psychiatrist in New York City, who has been in practice for over 25 years.
Connect with Dr.
Plutchik
More from Lori Plutchik M.D.
More from Psychology Today
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.